BioNTech SE (22UA)

Profile

https://www.biontech.de

BioNTech SE is a biotechnology company focused on the development of immunotherapies and mRNA-based medicines for cancer and infectious diseases. The company’s current portfolio includes oncology programs such as personalized and off-the-shelf cancer immunotherapies, cell therapies, and targeted biologic approaches designed to address hard-to-treat tumors. BioNTech also develops vaccine candidates and other immune-modulating treatments aimed at preventing or managing serious infectious diseases. Its work spans multiple platforms, including mRNA, protein-based therapies, and next-generation immunomodulators, reflecting a broad research and development base. BioNTech SE serves a central role in the biopharmaceutical market by advancing precision medicine approaches that combine molecular science with clinical development, supporting both preventative and therapeutic applications across global healthcare markets.